ZYBAN 150 MG — DIN 02238441
BUPROPION HYDROCHLORIDE : 150 MG · BAUSCH HEALTH, CANADA INC. · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is ZYBAN?
ZYBAN 150 MG contains BUPROPION HYDROCHLORIDE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02238441, held by BAUSCH HEALTH, CANADA INC., supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZYBAN used for?
Smoking cessation treatment in conjunction with behavioural modification.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Bupropion cost around the world?
Bupropion is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Sweden | AIP (pharmacy purchase price) | 9 | 33 | SEK███.██ |
| United States | acquisition | 2 | 26 | USD███.██ |
| Iceland | max wholesale | 6 | 11 | ISK███.██ |
| Morocco | PPV (public price) | 3 | 11 | MAD███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Romania | max producer price | 1 | 2 | RON███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
88 pack listings across 25 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Bupropion pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Bupropion in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Bupropion, across 32 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAUSCH HEALTH, CANADA INC. | 7 | 3 | BUPROPION HCL SR, BUPROPION HCL XL, WELLBUTRIN SR, WELLBUTRIN XL, ZYBAN | Sourceable in Canada |
| TEVA CANADA LIMITED | 4 | 2 | RATIO-BUPROPION SR, TEVA-BUPROPION XL | Sourceable in Canada |
| ODAN LABORATORIES LTD | 2 | 2 | ODAN BUPROPION SR | Sourceable in Canada |
| SUN PHARMA CANADA INC | 2 | 2 | TARO-BUPROPION XL | Sourceable in Canada |
| AVANSTRA INC | 2 | 0 | AVA-BUPROPION SR | No marketed DIN |
| DOMINION PHARMACAL | 2 | 0 | DOM-BUPROPION SR | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-BUPROPION XL | No marketed DIN |
| NOVOPHARM LIMITED | 2 | 0 | NOVO-BUPROPION SR, NOVO-BUPROPION SR TABLETS | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-BUPROPION SR | No marketed DIN |
| PHARMEL INC | 2 | 0 | PHL-BUPROPION SR | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | BUPROPION SR | No marketed DIN |
| SANIS HEALTH INC | 2 | 0 | BUPROPION SR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Kit containing 100 blistered tablets. |
| Storage | Not explicitly detailed in provided text (standard storage usually 15-30°C, but text refers to Section 11 which is not fully provided). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Bupropion |
|---|---|
| ATC code | N06AX12 |
| AHFS class | 28:16.04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02238441 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2238441 |
| Brand name | ZYBAN |
| Generic / active ingredient | BUPROPION HYDROCHLORIDE : 150 MG |
| Market authorization holder | BAUSCH HEALTH, CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | N06AX12 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06AX |
| Current status | MARKETED |
| Status date | 04-Jun-2021 |
| Original market date | 1998-08-10 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Start at 150 mg once daily for 3 days, then increase to 150 mg twice daily (at least 8 hours apart). Max 300 mg/day. Swallow whole. Target quit date in second week of treatment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; seizure disorders; bulimia/anorexia nervosa; abrupt withdrawal from alcohol/sedatives; concurrent MAOIs or thioridazine; use of other bupropion-containing products.
Warnings and precautions
Increased risk of self-harm and suicidal thinking. Dose-dependent seizure risk. Avoid in patients with Brugada syndrome. Monitor for hypertension. Do not crush or chew.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 32 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ODAN BUPROPION SR | 150 MG | TABLET (EXTENDED-RELEASE) | ODAN LABORATORIES LTD | MARKETED | 02275082 |
| ODAN BUPROPION SR | 100 MG | TABLET (EXTENDED-RELEASE) | ODAN LABORATORIES LTD | MARKETED | 02275074 |
| TARO-BUPROPION XL | 300 MG | TABLET (EXTENDED-RELEASE) | SUN PHARMA CANADA INC | MARKETED | 02475812 |
| TARO-BUPROPION XL | 150 MG | TABLET (EXTENDED-RELEASE) | SUN PHARMA CANADA INC | MARKETED | 02475804 |
| TEVA-BUPROPION XL | 300 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | 02439662 |
| TEVA-BUPROPION XL | 150 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | 02439654 |
| WELLBUTRIN XL | 300 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | 02275104 |
| WELLBUTRIN XL | 150 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | 02275090 |
| AVA-BUPROPION SR | 100 MG | TABLET (EXTENDED-RELEASE) | AVANSTRA INC | CANCELLED POST MARKET | 02363399 |
| AVA-BUPROPION SR | 150 MG | TABLET (EXTENDED-RELEASE) | AVANSTRA INC | CANCELLED POST MARKET | 02363402 |
2 · Same class — other molecules in ATC N06AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Venlafaxine | ACT VENLAFAXINE XR · APO-VENLAFAXINE XR · AURO-VENLAFAXINE XR · DOM-VENLAFAXINE XR · +19 more | 90 | 36 | Yes |
| Duloxetine | ACCEL-DULOXETINE · AG-DULOXETINE · APO-DULOXETINE · AURO-DULOXETINE · +24 more | 66 | 36 | Yes |
| Mirtazapine | APO-MIRTAZAPINE · AURO-MIRTAZAPINE · AURO-MIRTAZAPINE OD · AVA-MIRTAZAPINE · +24 more | 64 | 31 | Yes |
| Trazodone | AG-TRAZODONE · APO-TRAZODONE D TABLETS 150MG · APO-TRAZODONE TABLETS 100MG · APO-TRAZODONE TABLETS 50MG · +30 more | 57 | 21 | Yes |
| Desvenlafaxine | AG-DESVENLAFAXINE · APO-DESVENLAFAXINE · APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS · DESVENLAFAXINE · +8 more | 28 | 20 | Yes |
| Tryptophan | APO-TRYPTOPHAN · DOM-TRYPTOPHAN · PHL-TRYPTOPHAN · PMS-TRYPTOPHAN · +2 more | 20 | 11 | Yes |
| Bupropion | AVA-BUPROPION SR · BUPROPION HCL SR · BUPROPION HCL XL · BUPROPION SR · +13 more | 32 | 9 | Yes |
| Vortioxetine | APO-VORTIOXETINE · TRINTELLIX | 8 | 6 | Yes |
| Vilazodone | APO-VILAZODONE · VIIBRYD | 8 | 6 | Yes |
| Levomilnacipran | FETZIMA | 4 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N06AB | Citalopram · Escitalopram · Fluoxetine · Fluvoxamine · Paroxetine · +1 more | 589 | 248 |
| N06AA | Amitriptyline · Amoxapine · Clomipramine · Desipramine · Doxepin · +5 more | 325 | 62 |
| N06AG | Moclobemide | 21 | 4 |
| N06AF | Tranylcypromine | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ZYBAN called?
Also recorded in Canada as: 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet [Forfivo] (US), 12 HR bupropion hydrochloride 90 MG / naltrexone hydrochloride 8 MG Extended Release Oral Tablet [Contrave] (US), bupropion hydrochloride 105 MG / dextromethorphan hydrobromide 45 MG Extended Release Oral Tablet [Auvelity] (US), 12 HR bupropion hydrochloride 100 MG Extended Release Oral Tablet [Wellbutrin] (US), 12 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet [Wellbutrin] (US), 12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet [Wellbutrin] (US), 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet [Wellbutrin] (US), 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet [Wellbutrin] (US), 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet (US), 12 HR bupropion hydrochloride 90 MG / naltrexone hydrochloride 8 MG Extended Release Oral Tablet (US), Smoking Cessation 12 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet (US), bupropion hydrochloride 105 MG / dextromethorphan hydrobromide 45 MG Extended Release Oral Tablet (US), 12 HR bupropion hydrochloride 100 MG Extended Release Oral Tablet (US), 12 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet (US), 12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet (US).
The same molecule, Bupropion, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Bupropion Teva | Latin | Iceland, Sweden |
| Voxra | Latin | Sweden |
| Bupropion Accord | Latin | Sweden |
| Bupropion Bluefish | Latin | Sweden |
| Bupropion Sandoz | Latin | Sweden |
| Bupropion SUN | Latin | Sweden |
| Wellbutrin Retard (Lyfjaver) | Latin | Iceland |
| Bupropion Omet Pharma | Latin | Sweden |
| Bupropion Orion | Latin | Sweden |
| Bupropion Zentiva | Latin | Sweden |
| Wellbutrin Retard | Latin | Iceland |
| Wellbutrin XR (Heilsa) | Latin | Iceland |
| Wellbutrin XR (Lyfjaver) | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.